Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05558722
What this trial is testing

Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer

Who this might be right for
Breast Cancer Stage II
Xijing Hospital 31
Testing effectiveness (Phase 2)Study completedNCT03560531
What this trial is testing

ZN-c5 in Subjects With Breast Cancer

Who this might be right for
Breast Cancer
Zeno Alpha Inc. 181
Large-scale testing (Phase 3)Study completedNCT01881230
What this trial is testing

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)

Who this might be right for
Breast TumorBreast CancerCancer of the Breast+8 more
Celgene 191
Testing effectiveness (Phase 2)UnknownNCT05044988
What this trial is testing

HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer

Who this might be right for
HR+/HER2- Advanced and/or Metastatic Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 20
Testing effectiveness (Phase 2)Looking for participantsNCT06923527
What this trial is testing

Circulating Tumor DNA

Who this might be right for
ER+ Breast Cancer
Yale University 50
Not applicableUnknownNCT05814224
What this trial is testing

Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA

Who this might be right for
Hormone Receptor Positive Breast CarcinomaBreast NeoplasmsNeoplasms, Breast+4 more
Centro di Riferimento Oncologico - Aviano 164
Testing effectiveness (Phase 2)Looking for participantsNCT06201234
What this trial is testing

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast CancerAdvanced or Metastatic Breast CancerBRCA1 Mutation+1 more
GBG Forschungs GmbH 176
Early research (Phase 1)Ended earlyNCT04274933
What this trial is testing

Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

Who this might be right for
Breast CancerCancer
AbbVie 4
Early research (Phase 1)Ended earlyNCT06351332
What this trial is testing

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

Who this might be right for
Breast CancerBreast Cancer FemaleTriple Negative Breast Cancer+2 more
Filipa Lynce, MD 7
Early research (Phase 1)WithdrawnNCT04756505
What this trial is testing

Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Hormone Receptor Positive Breast AdenocarcinomaMetastatic Breast Carcinoma+2 more
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Ended earlyNCT03430466
What this trial is testing

Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Kyoto Breast Cancer Research Network 1
Early research (Phase 1)Active Not RecruitingNCT02779751
What this trial is testing

Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

Who this might be right for
Non Small Cell Lung CancerBreast Cancer
Eli Lilly and Company 100
Testing effectiveness (Phase 2)Study completedNCT02137083
What this trial is testing

A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Fudan University 22
Not applicableLooking for participantsNCT06781281
What this trial is testing

NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.

Who this might be right for
Breast Cancer Invasive
Henan Cancer Hospital 709
Testing effectiveness (Phase 2)Active Not RecruitingNCT04553133
What this trial is testing

PF-07104091 as a Single Agent and in Combination Therapy

Who this might be right for
Small Cell Lung CancerOvarian CancerBreast Cancer
Pfizer 157
Testing effectiveness (Phase 2)Ended earlyNCT05966584
What this trial is testing

Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 1
Large-scale testing (Phase 3)Study completedNCT01942135
What this trial is testing

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

Who this might be right for
Metastatic Breast Cancer
Pfizer 521
Testing effectiveness (Phase 2)Study completedNCT03691493
What this trial is testing

Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor PositiveHER2/Neu Negative+4 more
Emory University 36
Testing effectiveness (Phase 2)Study completedNCT03280563
What this trial is testing

Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Who this might be right for
Breast Neoplasms
Hoffmann-La Roche 144
Testing effectiveness (Phase 2)Looking for participantsNCT07647016
What this trial is testing

Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study

Who this might be right for
Breast Cancer
Fudan University 53
Next Page